DTaP / Tdap / Td
Tetanus, diphtheria, pertussis, polio, Hib (DTaP / Tdap / Td)
PENTACEL · INFANRIX-IPV/HIB · INFANRIX HEXA · QUADRACEL · ACT-HIB · IMOVAX POLIO · ADACEL · BOOSTRIX · ADACEL-POLIO · BOOSTRIX-POLIO · TD ADSORBED
Infant series, school-entry booster, and a booster every 10 years. Every product below is a Health Canada authorized vaccine; every schedule comes from the Canadian Immunization Guide.
Products authorized in Canada
Brand names and DINs (Drug Identification Numbers) as Health Canada's Drug Product Database lists them. The product monograph is the manufacturer's full prescribing information approved by Health Canada.
| Product | DIN | What it is | Presentation and age | Official information |
|---|---|---|---|---|
| PENTACEL | 02534797 | DTaP-IPV-Hib | 0.5 mL · suspension · intramuscular · 6 weeks to 6 years | Product guideHealth Canada recordProduct monograph (PDF) |
| INFANRIX-IPV/HIB | 02257122 | DTaP-IPV-Hib | 0.5 mL · suspension · intramuscular · 6 weeks to 6 years | Product guideHealth Canada recordProduct monograph (PDF) |
| INFANRIX HEXA | 02253852 | DTaP-IPV-Hib-HepB | 0.5 mL · suspension · intramuscular · 6 weeks to 6 years | Product guideHealth Canada recordProduct monograph (PDF) |
| QUADRACEL | 02534789 | DTaP-IPV | 0.5 mL · suspension · intramuscular · 4 to 6 years | Product guideHealth Canada recordProduct monograph (PDF) |
| ACT-HIB | 01959034 | Haemophilus influenzae type b conjugate (PRP-T) | 0.5 mL · powder for solution · intramuscular · 2 months and older | Product guideHealth Canada recordProduct monograph (PDF) |
| IMOVAX POLIO | 01959042 | Inactivated poliovirus (types 1, 2, 3) | 0.5 mL · solution · subcutaneous · 6 weeks and older | Product guideHealth Canada recordProduct monograph (PDF) |
| ADACEL | 02240255 | Tdap | 0.5 mL · suspension · intramuscular · 4 to 64 years | Product guideHealth Canada recordProduct monograph (PDF) |
| BOOSTRIX | 02247600 | Tdap | 0.5 mL · suspension · intramuscular · 4 years and older | Product guideHealth Canada recordProduct monograph (PDF) |
| ADACEL-POLIO | 02352044 | Tdap-IPV | 0.5 mL · suspension · intramuscular · 4 years and older | Product guideHealth Canada recordProduct monograph (PDF) |
| BOOSTRIX-POLIO | 02312557 | Tdap-IPV | 0.5 mL · suspension · intramuscular · 4 years and older | Product guideHealth Canada recordProduct monograph (PDF) |
| TD ADSORBED | 02528401 | Td (tetanus and diphtheria toxoids) | 0.5 mL · suspension · intramuscular · 7 years and older | Product guideHealth Canada recordProduct monograph (PDF) |
Pregnancy and breastfeeding
Pregnancy
Tdap is recommended in every pregnancy, irrespective of immunization history, ideally at 27 to 32 weeks. Polio (IPV) may be considered for a non-immune person at increased risk; Hib when a predisposing condition is present.
Breastfeeding
Tdap is recommended if no adult dose has been given; polio and Hib are used if indicated.
Source: Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026. Live vaccines are generally contraindicated in pregnancy; routinely recommended vaccines can be given while breastfeeding unless the chapter says otherwise.
How many doses
The schedules the Canadian Immunization Guide describes for this vaccine. Which one applies depends on age, health and product — use the dose planner to see the dates for your situation.
| Schedule | Doses | Who it is for | Products |
|---|---|---|---|
| DTaP-IPV-Hib — infant series (2, 4, 6 and 18 months) Four doses at 2, 4, 6 and 18 months of age. | 4 doses | Routine infant series with a DTaP-IPV-Hib-containing vaccine at 2, 4, 6 and 12 to 23 months (generally 18 months); the first dose can be given as early as 6 weeks. Minimum 4 weeks between primary doses and 6 months between dose 3 and the booster. Late starters follow a catch-up schedule set by your clinician. | PENTACEL, INFANRIX-IPV/HIB |
| DTaP-IPV-Hib-HepB (INFANRIX HEXA) — infant series Four doses at 2, 4, 6 and 18 months of age, including hepatitis B. | 4 doses | Six-in-one infant series used where hepatitis B is given in infancy. Doses at 2, 4, 6 and 12 to 23 months (generally 18 months). Infants born to mothers with hepatitis B need separate hepatitis B vaccine and immune globulin at birth. | INFANRIX HEXA |
| DTaP-IPV — school-entry booster (4 to 6 years) Single booster dose at 4 to 6 years of age. | 1 dose | DTaP-IPV or Tdap-IPV as the booster for children 4 to 6 years of age who completed the infant series. Not needed if the fourth infant dose was given at 4 years of age or older. | QUADRACEL |
| Hib (ACT-HIB) — infant series given separately Four doses at 2, 4, 6 and 18 months of age when Hib is given on its own. | 4 doses | Hib vaccine alone, when a combination product is not used. Children starting at 7 to 11 months need 2 doses plus a booster; at 12 to 14 months 1 dose plus a booster; at 15 to 59 months a single dose. Not routinely recommended after 5 years of age except for asplenia, stem-cell transplant and other high-risk conditions. | ACT-HIB |
| Polio (IPV) — primary series for people 7 and older never immunized Three doses at 0, 1 to 2 months and 6 to 12 months. | 3 doses | For people who were never immunized, or not fully immunized, against polio and need protection (travel, work, outbreak). Dose 2 at least 4 weeks after dose 1; dose 3 at least 6 months after dose 2. Infants and young children receive polio vaccine within a combination product instead. Adults who completed a series may need one lifetime booster for travel to polio-affected areas. | IMOVAX POLIO |
| Tdap — adolescent booster at 14 to 16 years One Tdap dose at 14 to 16 years as the first 10-year booster. | 1 dose | Tdap vaccine should be administered to adolescents at 14 to 16 years of age as the first 10-year booster dose after the childhood series. | ADACEL, BOOSTRIX |
| Tdap — adult booster, one dose One Tdap dose in adulthood, then Td or Tdap every 10 years. | 1 dose | Every adult should receive one Tdap dose if not previously immunized against pertussis as an adult, then Td (or Tdap) every 10 years. Also given to adults who will be in close contact with infants. Children 7 to 13 who missed the childhood series follow a catch-up schedule. | ADACEL, BOOSTRIX |
| Tdap in pregnancy — one dose every pregnancy One Tdap dose in every pregnancy, ideally between 27 and 32 weeks. | 1 dose | Recommended in every pregnancy regardless of previous Tdap, ideally at 27 to 32 weeks of gestation to protect the newborn. Immunization between 13 and 26 weeks may be considered when preterm delivery or travel is anticipated. | ADACEL, BOOSTRIX |
| Tdap-IPV — booster with polio, one dose One Tdap-IPV dose for people 4 years and older who need both pertussis and polio boosting. | 1 dose | Used as the 4 to 6 year school-entry booster in some provinces, and for adolescents or adults who need a polio booster together with Tdap (travel to polio-affected areas, incomplete polio series). | ADACEL-POLIO, BOOSTRIX-POLIO |
| Td — tetanus and diphtheria booster every 10 years One Td booster dose every 10 years after a completed primary series. | 1 dose | Routine booster every 10 years for people 7 years and older who completed a primary tetanus/diphtheria series. Tdap is preferred for the first adult booster. A wound may call for a dose sooner than 10 years. | TD ADSORBED |
| Td / Tdap — primary series for people 7 and older never immunized Three doses at 0, 1 to 2 months and 6 to 12 months; Tdap for the first dose. | 3 doses | For people 7 years and older with no or unknown tetanus/diphtheria immunization. Dose 1 is Tdap, then Td at 1 to 2 months and 6 to 12 months (minimum 4 weeks between doses 1 and 2, 6 months between doses 2 and 3). Polio vaccine is added if that series is also incomplete. | TD ADSORBED, ADACEL, BOOSTRIX |
Sources
- Pertussis (whooping cough) vaccines: Canadian Immunization Guide — Chapter revised March 2018
- Haemophilus influenzae type b (Hib) vaccines: Canadian Immunization Guide — Current online chapter
- Poliomyelitis (polio) vaccines: Canadian Immunization Guide — Current online chapter
- Tetanus toxoid: Canadian Immunization Guide — Current online chapter
- Health Canada Drug Product Database — product records and monographs
Clinical rules reviewed on 2026-09-27. General information from public Canadian guidance; a personal assessment is needed for treatment decisions. Care365 does not decide whether a vaccine is publicly funded in Ontario.